Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA

Author(s): Chengyu Hu, Kai Liu, Bei Wang, Wen Xu, Yexiang Lin and Chengfu Yuan*

Volume 27, Issue 9, 2021

Published on: 29 October, 2020

Page: [1211 - 1218] Pages: 8

DOI: 10.2174/1381612826666201029100151

Price: $65

Abstract

Background: There is increasing evidence that lncRNA, a type of transcript that is over 200 nucleotides in length and may serve as oncogenes or suppressor genes, is implicated in the pathophysiology of human diseases. In particular, tumorigenesis and progress are closely correlated with its abnormal expression. In addition, it may become a promising target for many oncology biotherapies. Abnormal DLX6-AS1 expression affects different cellular processes such as proliferation, aggression and metastasis. This review aims to probe into the pathophysiological functions and molecular mechanisms of DLX6-AS1 in various cancers.

Methods: By retrieving the literature, this review summarizes the biological function and mechanism of LncRNA DLX6-AS1 in tumor occurrence.

Results: The lncRNA DLX6-AS1 is a new tumor-related RNA that has recently been found to be aberrantly expressed in diverse cancers, such as pancreatic cancer, osteosarcoma, non-small cell lung cancer, gastric carcinoma, glioma, hepatocellular cancer, colorectal carcinoma, renal carcinoma, esophageal squamous cell cancer, ovarian cancer, Ewing sarcoma, cervical cancer, breast cancer, thyroid cancer, neuroblastoma, pulmonary adenocarcinoma, nasopharyngeal carcinoma, squamous laryngeal cancer and bladder cancer, etc. Meanwhile, it is identified that DLX6-AS1 regulates the aggression, translocation and proliferation of diverse cancers.

Conclusion: LncRNA DLX6-AS1 may be viable markers in tumors or a potential therapeutic target for multiple tumors.

Keywords: Long non-coding RNA, DLX6-AS1, therapeutic target, molecular mechanisms, tumors, oncogenes or suppressor genes.

« Previous Next »
[1]
Bergmann JH, Spector DL. Long non-coding RNAs: modulators of nuclear structure and function. Curr Opin Cell Biol 2014; 26: 10-8.
[http://dx.doi.org/10.1016/j.ceb.2013.08.005] [PMID: 24529241]
[2]
Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 2009; 23(13): 1494-504.
[http://dx.doi.org/10.1101/gad.1800909] [PMID: 19571179]
[3]
Tano K, Akimitsu N. Long non-coding RNAs in cancer progression. Front Genet 2012; 3: 219.
[http://dx.doi.org/10.3389/fgene.2012.00219] [PMID: 23109937]
[4]
Li J, Li P, Zhao W, et al. Expression of long non-coding RNA DLX6-AS1 in lung adenocarcinoma. Cancer Cell Int 2015; 15: 48.
[http://dx.doi.org/10.1186/s12935-015-0201-5] [PMID: 26052251]
[5]
Morini M, Astigiano S, Gitton Y, et al. Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231. BMC Cancer 2010; 10: 649.
[http://dx.doi.org/10.1186/1471-2407-10-649] [PMID: 21108812]
[6]
An Y, Chen XM, Yang Y, et al. LncRNA DLX6-AS1 promoted cancer cell proliferation and invasion by attenuating the endogenous function of miR-181b in pancreatic cancer. Cancer Cell Int 2018; 18: 143.
[http://dx.doi.org/10.1186/s12935-018-0643-7] [PMID: 30250401]
[7]
Yang J, Ye Z, Mei D, Gu H, Zhang J. Long noncoding RNA DLX6-AS1 promotes tumorigenesis by modulating miR-497-5p/FZD4/FZD6/Wnt/β-catenin pathway in pancreatic cancer. Cancer Manag Res 2019; 11: 4209-21.
[http://dx.doi.org/10.2147/CMAR.S194453] [PMID: 31118816]
[8]
Zhang RM, Tang T, Yu HM, Yao XD. LncRNA DLX6-AS1/miR-129-5p/DLK1 axis aggravates stemness of osteosarcoma through Wnt signaling. Biochem Biophys Res Commun 2018; 507(1-4): 260-6.
[http://dx.doi.org/10.1016/j.bbrc.2018.11.019] [PMID: 30442366]
[9]
Zhang N, Meng X, Mei L, Zhao C, Chen W. LncRNA DLX6-AS1 promotes tumor proliferation and metastasis in osteosarcoma through modulating miR-641/HOXA9 signaling pathway. J Cell Biochem 2019.
[http://dx.doi.org/10.1002/jcb.28426] [PMID: 30838699]
[10]
Li X, Zhang H, Wu X. Long noncoding RNA DLX6-AS1 accelerates the glioma carcinogenesis by competing endogenous sponging miR-197-5p to relieve E2F1. Gene 2019; 686: 1-7.
[http://dx.doi.org/10.1016/j.gene.2018.10.065] [PMID: 30366080]
[11]
Liang Y, Zhang C-D, Zhang C, Dai D-Q. DLX6-AS1/miR-204-5p/OCT1 positive feedback loop promotes tumor progression and epithelial-mesenchymal transition in gastric cancer. Gastric Cancer 2020; 23(2): 212-27.
[http://dx.doi.org/10.1007/s10120-019-01002-1] [PMID: 31463827]
[12]
Fu X, Tian Y, Kuang W, Wen S, Guo W. Long non-coding RNA DLX6-AS1 silencing inhibits malignant phenotypes of gastric cancer cells. Exp Ther Med 2019; 17(6): 4715-22.
[http://dx.doi.org/10.3892/etm.2019.7521] [PMID: 31105791]
[13]
Wu Q, Ma J, Meng W, Hui P. DLX6-AS1 promotes cell proliferation, migration and EMT of gastric cancer through FUS-regulated MAP4K1. Cancer Biol Ther 2020; 21(1): 17-25.
[http://dx.doi.org/10.1080/15384047.2019.1647050] [PMID: 31591939]
[14]
Sun W, Zhang L, Yan R, Yang Y, Meng X. LncRNA DLX6-AS1 promotes the proliferation, invasion, and migration of non-small cell lung cancer cells by targeting the miR-27b-3p/GSPT1 axis. OncoTargets Ther 2019; 12: 3945-54.
[http://dx.doi.org/10.2147/OTT.S196865] [PMID: 31190891]
[15]
Huang Y, Ni R, Wang J, Liu Y. Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer. Biomed Pharmacother 2019; 109: 1851-9.
[http://dx.doi.org/10.1016/j.biopha.2018.09.151] [PMID: 30551440]
[16]
Li D, Tang X, Li M, Zheng Y. Long noncoding RNA DLX6-AS1 promotes liver cancer by increasing the expression of WEE1 via targeting miR-424-5p. J Cell Biochem 2019; 120(8): 12290-9.
[http://dx.doi.org/10.1002/jcb.28493] [PMID: 30805988]
[17]
Zhang L, He X, Jin T, Gang L, Jin Z. Long non-coding RNA DLX6-AS1 aggravates hepatocellular carcinoma carcinogenesis by modulating miR-203a/MMP-2 pathway. Biomed Pharmacother 2017; 96: 884-91.
[http://dx.doi.org/10.1016/j.biopha.2017.10.056] [PMID: 29145165]
[18]
Wu D-M, Zheng ZH, Zhang YB, et al. Down-regulated lncRNA DLX6-AS1 inhibits tumorigenesis through STAT3 signaling pathway by suppressing CADM1 promoter methylation in liver cancer stem cells. J Exp Clin Cancer Res 2019; 38(1): 237.
[http://dx.doi.org/10.1186/s13046-019-1239-3] [PMID: 31171015]
[19]
Yang B, et al. LncRNA DLX6-AS1 increases the expression of HIF-1α and promotes the malignant phenotypes of nasopharyngeal carcinoma cells via targeting MiR-199a-5p. Mol Genet Genomic Med 2020; 8(1)e1017
[20]
Zhang JJ, Xu WR, Chen B, Z JJ, et al. The up-regulated lncRNA DLX6-AS1 in colorectal cancer promotes cell proliferation, invasion and migration via modulating PI3K/AKT/mTOR pathway. Eur Rev Med Pharmacol Sci 2019; 23(19): 8321-31.
[PMID: 31646562]
[21]
Zhou FR, Shen F, Z FR, et al. Long noncoding RNA DLX6-AS1 functions as a competing endogenous RNA for miR-577 to promote malignant development of colorectal cancer. Eur Rev Med Pharmacol Sci 2019; 23(9): 3742-8.
[PMID: 31115000]
[22]
Wu SB, Wang HQWSB. Upregulation of long noncoding RNA DLX6-AS1 promotes cell growth and metastasis in esophageal squamous cell carcinoma via targeting miR-577. Eur Rev Med Pharmacol Sci 2020; 24(3): 1195-201.
[PMID: 32096208]
[23]
Wang M, Li Y, Yang Y, W M, et al. Long non coding RNA DLX6 AS1 is associated with malignant progression and promotes proliferation and invasion in esophageal squamous cell carcinoma. Mol Med Rep 2019; 19(3): 1942-50.
[PMID: 30592268]
[24]
You Q, Shi HY, Gong CF, Tian XY, Li SYQ. Long non-coding RNA DLX6-AS1 acts as an oncogene by targeting miR-613 in ovarian cancer. Eur Rev Med Pharmacol Sci 2019; 23(15): 6429-35.
[PMID: 31378881]
[25]
Zhao P, Guan H, Dai Z, Ma Y, Zhao Y, Liu D. Long noncoding RNA DLX6-AS1 promotes breast cancer progression via miR-505-3p/RUNX2 axis. Eur J Pharmacol 2019.865172778
[http://dx.doi.org/10.1016/j.ejphar.2019.172778] [PMID: 31705901]
[26]
Wang P, Xue L, Wang L, Tang H, Lv C, Xue Q. Long noncoding RNA DLX6-AS1 promotes migration and invasion of breast cancer cells by upregulating FUS. Panminerva Med 2020.
[PMID: 31961108]
[27]
Tian Y, Wang YR, Jia SHTY. Knockdown of long noncoding RNA DLX6-AS1 inhibits cell proliferation and invasion of cervical cancer cells by downregulating FUS. Eur Rev Med Pharmacol Sci 2019; 23(17): 7307-13.
[PMID: 31539117]
[28]
Lei X, Yang S, Yang Y, et al. Long noncoding RNA DLX6-AS1 targets miR-124-3p/CDK4 to accelerate Ewing’s sarcoma. Am J Transl Res 2019; 11(10): 6569-76.
[PMID: 31737208]
[29]
Zhang HY, Xing MQ, Guo J, Z HY, et al. Long noncoding RNA DLX6-AS1 promotes neuroblastoma progression by regulating miR-107/BDNF pathway. Cancer Cell Int 2019; 19: 313.
[http://dx.doi.org/10.1186/s12935-019-0968-x] [PMID: 31787850]
[30]
Zhong ZB, Wu YJ, Luo JN, Z ZB, et al. Knockdown of long noncoding RNA DLX6-AS1 inhibits migration and invasion of thyroid cancer cells by upregulating UPF1. Eur Rev Med Pharmacol Sci 2019; 23(24): 10867-73.
[PMID: 31858555]
[31]
Zeng X, Hu Z, Ke X, et al. Long noncoding RNA DLX6-AS1 promotes renal cell carcinoma progression via miR-26a/PTEN axis. Cell Cycle 2017; 16(22): 2212-9.
[http://dx.doi.org/10.1080/15384101.2017.1361072] [PMID: 28881158]
[32]
Guo J, Chen Z, Jiang H, et al. The lncRNA DLX6-AS1 promoted cell proliferation, invasion, migration and epithelial-to-mesenchymal transition in bladder cancer via modulating Wnt/β-catenin signaling pathway. Cancer Cell Int 2019; 19: 312.
[http://dx.doi.org/10.1186/s12935-019-1010-z] [PMID: 31787849]
[33]
Fang C, Xu L, He W, Dai J, Sun F. Long noncoding RNA DLX6-AS1 promotes cell growth and invasiveness in bladder cancer via modulating the miR-223-HSP90B1 axis. Cell Cycle 2019; 18(23): 3288-99.
[http://dx.doi.org/10.1080/15384101.2019.1673633] [PMID: 31615303]
[34]
Yang Q, Sun J, Ma Y, Zhao C, Song JYQ. LncRNA DLX6-AS1 promotes laryngeal squamous cell carcinoma growth and invasion through regulating miR-376c. Am J Transl Res 2019; 11(11): 7009-17.
[PMID: 31814904]
[35]
Tan JY, Sirey T, Honti F, et al. Extensive microRNA-mediated crosstalk between lncRNAs and mRNAs in mouse embryonic stem cells. Genome Res 2015; 25(5): 655-66.
[http://dx.doi.org/10.1101/gr.181974.114] [PMID: 25792609]
[36]
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127(12): 2893-917.
[http://dx.doi.org/10.1002/ijc.25516] [PMID: 21351269]
[37]
Strobel O, Hank T, Hinz U, et al. Pancreatic cancer surgery: The New R-status counts. Ann Surg 2017; 265(3): 565-73.
[http://dx.doi.org/10.1097/SLA.0000000000001731] [PMID: 27918310]
[38]
Jiang C, Yang Y, Yang Y, et al. Long Noncoding RNA (lncRNA) HOTAIR affects tumorigenesis and metastasis of non-small cell lung cancer by upregulating miR-613. Oncol Res 2018; 26(5): 725-34.
[http://dx.doi.org/10.3727/096504017X15119467381615] [PMID: 29187267]
[39]
Cheng Z, Li Z, Ma K, et al. Long Non-coding RNA XIST promotes glioma tumorigenicity and angiogenesis by acting as a molecular sponge of miR-429. J Cancer 2017; 8(19): 4106-16.
[http://dx.doi.org/10.7150/jca.21024] [PMID: 29187887]
[40]
Zhao W, Yuan H, Ren X, Huang K, Guo Z. Association between expression of HOTAIR and invasiveness of gliomas, and its predictive value advances in clinical and experimental medicine: official organ Wroclaw Medical University 2019 ; 28: 1179-83..
[41]
Song P, Yin SC. Long non-coding RNA EWSAT1 promotes human nasopharyngeal carcinoma cell growth in vitro by targeting miR-326/-330-5p. Aging (Albany NY) 2016; 8(11): 2948-60.
[http://dx.doi.org/10.18632/aging.101103] [PMID: 27816050]
[42]
Xin Y, Li Z, Shen J, Chan MT, Wu WK. CCAT1: a pivotal oncogenic long non-coding RNA in human cancers. Cell Prolif 2016; 49(3): 255-60.
[http://dx.doi.org/10.1111/cpr.12252] [PMID: 27134049]
[43]
Li J, Li Z, Zheng W, et al. LncRNA-ATB: An indispensable cancer-related long noncoding RNA. Cell Prolif 2017; 50(6)e12381
[http://dx.doi.org/10.1111/cpr.12381] [PMID: 28884871]
[44]
Sun K, Zhang G. Long noncoding RNA CASC2 suppresses esophageal squamous cell carcinoma progression by increasing SOCS1 expression. Cell Biosci 2019; 9: 90.
[http://dx.doi.org/10.1186/s13578-019-0353-4] [PMID: 31728180]
[45]
Chang ZW, Jia YX, Zhang WJ, et al. LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1. J Exp Clin Cancer Res 2018; 37(1): 56.
[http://dx.doi.org/10.1186/s13046-018-0724-4] [PMID: 29530057]
[46]
Wu L, Gong Y, Yan T, Zhang H. LINP1 Promotes the progression of cervical cancer by scaffolding EZH2, LSD1 and DNMT1 to inhibit the expression of KLF2 and PRSS8. Biochem Cell Biol 2020; 98(5): 591-9.
[47]
Yang H, Zhang X, Zhao Y, et al. Downregulation of lncRNA XIST represses tumor growth and boosts radiosensitivity of neuroblastoma via modulation of the miR-375/L1CAM axis. Neurochem Res 2020; 45(11): 2679-90.
[http://dx.doi.org/10.1007/s11064-020-03117-9] [PMID: 32857295]

Rights & Permissions Print Cite
Article Metrics
34
1
© 2024 Bentham Science Publishers | Privacy Policy